DK3313833T3 - Forbindelser og anvendelse deraf som inhibitorer af n-myristoyl-transferase - Google Patents

Forbindelser og anvendelse deraf som inhibitorer af n-myristoyl-transferase Download PDF

Info

Publication number
DK3313833T3
DK3313833T3 DK16736218.5T DK16736218T DK3313833T3 DK 3313833 T3 DK3313833 T3 DK 3313833T3 DK 16736218 T DK16736218 T DK 16736218T DK 3313833 T3 DK3313833 T3 DK 3313833T3
Authority
DK
Denmark
Prior art keywords
compounds
transferase inhibitors
myristoyl transferase
myristoyl
inhibitors
Prior art date
Application number
DK16736218.5T
Other languages
English (en)
Inventor
Andrew Simon Bell
Edward William Tate
Robin John Leatherbarrow
Jennie Ann Hutton
James Antony Brannigan
Original Assignee
Imperial College Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial College Innovations Ltd filed Critical Imperial College Innovations Ltd
Application granted granted Critical
Publication of DK3313833T3 publication Critical patent/DK3313833T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK16736218.5T 2015-06-29 2016-06-29 Forbindelser og anvendelse deraf som inhibitorer af n-myristoyl-transferase DK3313833T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1511382.2A GB201511382D0 (en) 2015-06-29 2015-06-29 Novel compounds and their use in therapy
PCT/GB2016/000134 WO2017001812A1 (en) 2015-06-29 2016-06-29 Compounds and their use as inhibitors of n-myristoyl transferase

Publications (1)

Publication Number Publication Date
DK3313833T3 true DK3313833T3 (da) 2021-02-15

Family

ID=53872374

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16736218.5T DK3313833T3 (da) 2015-06-29 2016-06-29 Forbindelser og anvendelse deraf som inhibitorer af n-myristoyl-transferase

Country Status (7)

Country Link
US (3) US10759804B2 (da)
EP (1) EP3313833B1 (da)
DK (1) DK3313833T3 (da)
ES (1) ES2860629T3 (da)
GB (1) GB201511382D0 (da)
PL (1) PL3313833T3 (da)
WO (1) WO2017001812A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
GB201820659D0 (en) * 2018-12-19 2019-01-30 Imperial Innovations Ltd Novel compostions and their use in therapy
GB201820660D0 (en) 2018-12-19 2019-01-30 Imperial Innovations Ltd Cancer treatments
WO2021008512A1 (zh) * 2019-07-18 2021-01-21 石药集团中奇制药技术(石家庄)有限公司 作为nmt抑制剂的化合物及其应用
IL295374A (en) 2020-02-04 2022-10-01 Mindset Pharma Inc 3-pyrrolidine indole derivatives as serotonergic psychedelics for the treatment of central nervous system disorders
GB202014736D0 (en) 2020-09-18 2020-11-04 Imperial College Innovations Ltd Novel compounds and their use in therapy
EP4232032A1 (en) * 2020-10-20 2023-08-30 Pacylex Pharmaceuticals Inc. Use of n-myristoyl transferase (nmt) inhibitors in the treatment of cancer, autoimmune disorders, and inflammatory disorders
GB202017367D0 (en) 2020-11-02 2020-12-16 Imperial College Innovations Ltd Novel use
WO2023114844A1 (en) * 2021-12-15 2023-06-22 Delix Therapeutics, Inc. Imidazopyridine psychoplastogens and uses thereof
WO2024052684A1 (en) 2022-09-09 2024-03-14 MyricX Pharma Limited Antibody drug conjugate comprising nmt inhibitor and its use

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2917511A (en) 1958-01-30 1959-12-15 Merck & Co Inc Bicyclic-nitrogen-heterocyclic compounds
US3050525A (en) 1960-12-14 1962-08-21 John B Bicking Certain derivatives of s-triazolo [4, 3-a]-pyridine
US3145215A (en) 1961-12-19 1964-08-18 Sterling Drug Inc Indazole derivatives
US3457269A (en) 1967-02-24 1969-07-22 Sterling Drug Inc N-substituted phenyl and n-substituted phenylalkyl 3 - indazolecarboxamides and preparation thereof
US3705175A (en) 1969-04-01 1972-12-05 Egyt Gyogyszervegyeszeti Gyar Indazole-3-carboxylic amides
US3678059A (en) 1969-10-07 1972-07-18 Ciba Geigy Corp 3-aminoalkylidene-indazoles
GB8623142D0 (en) 1986-09-26 1986-10-29 Beecham Group Plc Compounds
EP0498466B1 (en) 1985-04-27 2002-07-24 F. Hoffmann-La Roche Ag Indazole-3-carboxamide and -3-carboxylic acid derivatives
JPS63310891A (ja) 1987-06-12 1988-12-19 Yoshitomi Pharmaceut Ind Ltd 縮合ピリダジン化合物
DE3827253A1 (de) 1987-08-20 1989-03-02 Sandoz Ag Ester und amide von cyclischen carbonsaeuren und cyclischen alkoholen und aminen sowie verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
NZ230068A (en) 1988-07-29 1991-07-26 Dainippon Pharmaceutical Co Indazole-3-carboxylic acid esters and amides of diaza compounds having 6,7, or 8 ring members: preparatory processes and pharmaceutical compositions
EP0410509A1 (en) 1989-07-25 1991-01-30 Duphar International Research B.V New substituted 1H-indazole-3-carboxamides
JPH03223280A (ja) 1990-01-26 1991-10-02 Dainippon Pharmaceut Co Ltd インダゾール―3―カルボキサミド誘導体の新規製造方法
WO1992004025A1 (en) 1990-08-31 1992-03-19 Warner-Lambert Company Amino acid analogs as cck antagonists
GB9020927D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Pharmaceuticals
JPH05230057A (ja) 1990-11-27 1993-09-07 Dainippon Pharmaceut Co Ltd 光学活性インダゾール―3―カルボキサミド誘導体及びそれを有効成分とする制吐剤
EP0494774A1 (en) 1991-01-11 1992-07-15 MERCK SHARP & DOHME LTD. Indazole-substituted fivemembered heteroaromatic compounds
JP3026845B2 (ja) 1991-02-20 2000-03-27 日清製粉株式会社 ピペリジン誘導体
EP0517984A1 (en) 1991-06-11 1992-12-16 Merrell Dow Pharmaceuticals Inc. Derivatives of amide analogs of certain methano bridged quinolizines
NZ243065A (en) 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
AU2435092A (en) 1991-08-20 1993-03-16 Smithkline Beecham Plc 5-ht4 receptor antagonists
AU2871592A (en) 1991-10-11 1993-05-03 Du Pont Merck Pharmaceutical Company, The Cyclic ureas and analogues useful as retroviral protease inhibitiors
JPH06135960A (ja) 1991-12-25 1994-05-17 Dainippon Pharmaceut Co Ltd インダゾール−3−カルボキサミド誘導体
US5190953A (en) 1992-03-26 1993-03-02 A. H. Robins Company, Incorporated Heterocyclic carboxylic acid amides and esters of azabicyclic compounds as gastric prokinetic, antiemetic, anxiolytic and antiarrhythmic agents
TW251287B (da) 1993-04-30 1995-07-11 Nissei Co Ltd
CA2160420A1 (en) 1994-10-20 1996-04-21 Haruhiko Kikuchi 5-ht4 receptor agonists
ZA951822B (en) 1994-12-23 1996-09-26 Glaxo Group Ltd Chemical compounds
IL117438A (en) 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
KR19990022096A (ko) 1995-05-31 1999-03-25 쇼다 오사무 모노시클릭 아미노기를 갖는 인다졸 유도체
WO1998043969A1 (en) 1997-03-31 1998-10-08 Dupont Pharmaceuticals Company Indazoles of cyclic ureas useful as hiv protease inhibitors
US6069152A (en) 1997-10-07 2000-05-30 Eli Lilly And Company 5-HT4 agonists and antagonists
US5914405A (en) 1997-10-07 1999-06-22 Eli Lilly And Company Process for preparing 3-substituted indazoles
JPH11279156A (ja) 1998-03-31 1999-10-12 Dai Ichi Seiyaku Co Ltd インダゾール誘導体
US6458781B1 (en) 1998-04-27 2002-10-01 David Thomas Connor Substituted diarylalkyl amides as calcium channel antagonists
EP1080078B1 (en) 1998-05-22 2006-02-01 Scios Inc. Heterocyclic compounds and methods to treat cardiac failure and other disorders
US6303625B1 (en) 1998-07-27 2001-10-16 Ortho-Mcneil Pharmaceutical, Inc. Triazolopyridines for the treatment of thrombosis disorders
JP3435404B2 (ja) 1998-12-18 2003-08-11 バジリア ファルマスーチカ アーゲー 新規な二環式化合物
GB2345486A (en) 1999-01-11 2000-07-12 Glaxo Group Ltd Heteroaromatic protein tyrosine kinase inhibitors
FR2792318B1 (fr) 1999-04-16 2001-06-15 Synthelabo Derives d'indazole, leur preparation et leur application en therapeutique
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
GB0002666D0 (en) 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
WO2001058869A2 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
KR100423899B1 (ko) 2000-05-10 2004-03-24 주식회사 엘지생명과학 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
WO2002051232A2 (en) 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Novel benzazepines and related heterocyclic derivatives
CA2440222C (en) 2001-03-09 2008-11-18 Pfizer Products Inc. Triazolopyridines as anti-inflammatory agents
US7094909B2 (en) 2001-06-11 2006-08-22 Agouron Pharmaceuticals, Inc. HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
HN2002000136A (es) 2001-06-11 2003-07-31 Basf Ag Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis
JPWO2002100833A1 (ja) 2001-06-12 2004-09-24 住友製薬株式会社 Rhoキナーゼ阻害剤
EP1401831A1 (en) 2001-07-03 2004-03-31 Chiron Corporation Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors
WO2003024969A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
BR0212613A (pt) 2001-09-19 2004-08-31 Pharmacia Corp Compostos de indazol substituìdos para o tratamento de inflamação
US7671054B1 (en) 2001-10-12 2010-03-02 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
FR2836915B1 (fr) 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
FR2836914B1 (fr) 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
US20040014764A1 (en) 2002-03-29 2004-01-22 Smith Charles D. N-myristoyltransferase inhibitor compositions and methods of use
GB0218625D0 (en) 2002-08-10 2002-09-18 Astex Technology Ltd Pharmaceutical compounds
PA8579601A1 (es) 2002-08-30 2004-05-07 Pfizer Prod Inc Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
US7005523B2 (en) 2002-08-30 2006-02-28 Pfizer Inc. Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
MY139563A (en) 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
FR2845382A1 (fr) 2002-10-02 2004-04-09 Sanofi Synthelabo Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique
JP2006517580A (ja) 2003-02-14 2006-07-27 ファイザー・プロダクツ・インク 抗炎症化合物としてのトリアゾロピリジン
DE10309255B4 (de) 2003-02-25 2007-09-13 4TECH Gesellschaft für Technologie- und Know-how-Transfer mbH Verfahren und Schaltungen zur Erkennung unidirektionaler Fehler
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
WO2005012258A1 (ja) 2003-07-30 2005-02-10 Kyowa Hakko Kogyo Co., Ltd. タンパク質キナーゼ阻害剤
ATE553092T1 (de) 2003-07-30 2012-04-15 Kyowa Hakko Kirin Co Ltd Indazolderivate
US7008953B2 (en) 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
WO2005014554A1 (en) 2003-08-08 2005-02-17 Astex Therapeutics Limited 1h-indazole-3-carboxamide compounds as mapkap kinase modulators
TWI344961B (en) 2003-10-15 2011-07-11 Ube Industries Novel indazole derivative
EP1593671A1 (en) 2004-03-05 2005-11-09 Graffinity Pharmaceuticals AG DPP-IV inhibitors
JP4084836B2 (ja) 2004-08-12 2008-04-30 ファイザー・インク p38MAPキナーゼインヒビターとしてのトリアゾロピリジニルスルファニル誘導体
MX2007002050A (es) 2004-08-18 2007-03-29 Pharmacia & Upjohn Co Llc Compuestos de triazolopiridina.
BRPI0514391A (pt) 2004-08-18 2008-06-10 Pharmacia & Upjohn Co Llc compostos de triazolopiridina para o tratamento de inflamação
JP5159317B2 (ja) 2004-12-22 2013-03-06 セラヴァンス, インコーポレーテッド インダゾール−カルボキサミド化合物
EP1674464A1 (en) 2004-12-23 2006-06-28 Santhera Pharmaceuticals (Schweiz) GmbH Novel thrombin inhibitors
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
GB0602178D0 (en) 2006-02-03 2006-03-15 Merck Sharp & Dohme Therapeutic treatment
US20090291968A1 (en) 2006-03-23 2009-11-26 Guy Georges Substituted indazole derivatives, their manufacture and use as pharmaceutical agents
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
WO2008021781A1 (en) 2006-08-07 2008-02-21 Incyte Corporation Triazolotriazines as kinase inhibitors
EP2076492A4 (en) 2006-10-06 2010-12-22 Merck Sharp & Dohme NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
WO2008040995A1 (en) 2006-10-07 2008-04-10 Peakdale Molecular Limited Indazoles for use as dpp-iv inhibitors
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
NZ581698A (en) 2007-06-05 2012-09-28 Merck Sharp & Dohme Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
US8207179B2 (en) 2007-06-12 2012-06-26 Boehringer Ingelheim International Gmbh Substituted indolines as tyrosine kinase inhibitors
EP2170337A4 (en) 2007-06-28 2013-12-18 Abbvie Inc NEW TRIAZOLOPYRIDAZINE
SA109300309B1 (ar) 2008-05-20 2013-01-22 باير شيرنج فارما ايه جي مشتقات فينيل وبنزو داي أوكسينيل إندازول بها استبدال
MX2011000460A (es) 2008-07-18 2011-03-15 Takeda Pharmaceutical Derivados de benzazepina y su uso como antagonistas de histamina h3.
GB0815947D0 (en) 2008-09-02 2008-10-08 Univ Dundee Compounds
EP2415765A4 (en) 2009-03-30 2012-08-15 Astellas Pharma Inc PYRIMIDINE COMPOUND
CA2770724A1 (en) * 2009-08-10 2011-02-17 Galenea Corporation 5-ht inhibiting indole compounds
WO2012065297A1 (en) 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
WO2012078777A1 (en) 2010-12-09 2012-06-14 Amgen Inc. Bicyclic compounds as pim inhibitors
WO2012095781A1 (en) 2011-01-13 2012-07-19 Pfizer Limited Indazole derivatives as sodium channel inhibitors
EP2734199B1 (en) 2011-07-22 2022-11-16 Pacylex Pharmaceuticals Inc. Synthetic lethality and the treatment of cancer
CA2838784A1 (en) 2011-08-12 2013-02-21 F. Hoffmann-La Roche Ag Pyrazolo[3,4-c]pyridine compounds and methods of use
IN2014CN02646A (da) 2011-09-14 2015-08-07 Samumed Llc
GB201120993D0 (en) * 2011-12-06 2012-01-18 Imp Innovations Ltd Novel compounds and their use in therapy
EP2807157A1 (en) 2012-01-27 2014-12-03 Novartis AG 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
KR101869534B1 (ko) 2012-03-05 2018-06-20 한국화학연구원 신규한 트리아졸로 피리다진 유도체 및 그의 용도
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy

Also Published As

Publication number Publication date
US20220411431A1 (en) 2022-12-29
US10759804B2 (en) 2020-09-01
PL3313833T3 (pl) 2021-06-28
US20180370974A1 (en) 2018-12-27
EP3313833A1 (en) 2018-05-02
US20200339586A1 (en) 2020-10-29
GB201511382D0 (en) 2015-08-12
EP3313833B1 (en) 2021-01-06
US11466011B2 (en) 2022-10-11
ES2860629T3 (es) 2021-10-05
WO2017001812A1 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
DK3277681T3 (da) Imidazolonylquinoliner og deres anvendelse som atm-kinaseinhibitorer
DK3277677T3 (da) 1-cyano-pyrrolidinforbindelser som usp30-hæmmere
DK3888658T3 (da) Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil
DK3495023T3 (da) Semifluorerede forbindelser og sammensætninger deraf
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3185868T3 (da) Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme
DK3536685T3 (da) Bicyklisk-fusionerede heteroaryl- eller arylforbindelser og anvendelse deraf som irak4 inhibitorer
DK3221306T3 (da) Heteroarylforbindelser som irak-inhibitorer og anvendelser deraf
DK3313833T3 (da) Forbindelser og anvendelse deraf som inhibitorer af n-myristoyl-transferase
DK3371190T3 (da) Heterocykliske forbindelser som pi3k-gamma-inhibitorer
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3137605T3 (da) Sammensætninger og fremgangsmåder til modulering af angiopoietin-lignende-3-ekspression
DK3105218T3 (da) Cyclopropylaminer som lsd1-inhibitorer
DK3442972T3 (da) Bromdomænehæmmere
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3105226T3 (da) Cyclopropylaminer som lsd1-inhibitorer
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3092256T3 (da) Forbindelser og sammensætninger til immunterapi
DK3511319T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3317400T3 (da) Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter
DK3663290T3 (da) Polymethinforbindelser og anvendelse deraf som fluorescerende markører
DK3144001T3 (da) Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
DK3393655T3 (da) Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3538528T3 (da) Pyrrolamider som alpha v-integrinhæmmere
DK3102555T3 (da) Sammensætninger af forbindelser og anvendelser deraf